Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orion trial: Nivolumab for recurrent/metastatic olfactory neuroblastoma
jRCT1031240654Phase 2Recruiting
- Sponsor
- Japan Research Foundation for Clinical Pharmacology
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in esthesioneuroblastoma (ENB), sponsored by Japan Research Foundation for Clinical Pharmacology. Primary endpoint: Objective response rate. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
esthesioneuroblastoma (ENB)
Beyond the preview
Go deeper on jRCT1031240654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240654.